Related Content
- Sanofi successfully switches Allegra
- Sandoz announces FDA approval, U.S. launch of chemotherapy drug
- Watson seeks FDA approval for generic Welchol
- FDA opens dialogue of incorporating technology, pharmacy into switch paradigm
- New alliance will crack down on adulterated products touting dietary supplement claims
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.
The drug maker announced the approval of Nulecit (sodium ferric gluconate complex in sucrose), an injectable and generic version of Sanofi-Aventis’ Ferrlecit.
The drug is used to treat iron deficiency anemia in adults and children ages 6 years and older undergoing chronic hemodialysis and receiving supplemental epoetin therapy.
